Northwest Biotherapeutics Inc NWBO Stock Analysis
- PINK
- Stock
- Market closed · opens Monday 9:30 AM ET
$0.17 up $0.00, 1.03% at close Nov 6
Last close · Previous close $0.16
- 52-week change
- Price only
- Distributions
- Per share, last 12 months
- Dividend yield
- NoneLast 12 months
Price chart
$0.17up $0.02, 14.03%Past month
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$0.16Nov 5
- Volume4.29MNov 6 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume6.27MLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $0.14 to $0.34; now $0.17
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 6 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
NWBO beat the S&P 500 in 1 of 7 periods.
| Period | NWBO and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | NWBO: up 14.0% S&P 500: down 5.6% | NWBO beat the S&P 500 by 19.6 percentage points Beat |
| 3M | NWBO: down 6.7% S&P 500: down 4.1% | NWBO trailed the S&P 500 by 2.6 percentage points Trailed |
| YTD | NWBO: down 27.2% S&P 500: up 8.7% | NWBO trailed the S&P 500 by 35.9 percentage points Trailed |
| 1Y | NWBO: down 29.6% S&P 500: up 10.9% | NWBO trailed the S&P 500 by 40.5 percentage points Trailed |
| Long term | ||
| 3Y | NWBO: down 79.4% S&P 500: up 75.0% −41.0% vs +20.5% a year | NWBO trailed the S&P 500 by 154.4 percentage points Trailed |
| 5Y | NWBO: down 85.5% S&P 500: up 67.8% −32.1% vs +10.9% a year | NWBO trailed the S&P 500 by 153.3 percentage points Trailed |
| 10Y | NWBO: down 63.0% S&P 500: up 313.1% −9.5% vs +15.2% a year | NWBO trailed the S&P 500 by 376.1 percentage points Trailed |
$10,000 invested in NWBO 10 years ago (Nov 4, 2016) would be worth about $3,700 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $41,313.
NWBO beat the S&P 500 in 1 of 7 periods.
| Period | NWBO and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | NWBO: up 14.0% S&P 500: down 5.6% | NWBO beat the S&P 500 by 19.6 percentage points Beat |
| 3M | NWBO: down 6.7% S&P 500: down 4.3% | NWBO trailed the S&P 500 by 2.4 percentage points Trailed |
| YTD | NWBO: down 27.2% S&P 500: up 7.8% | NWBO trailed the S&P 500 by 35.0 percentage points Trailed |
| 1Y | NWBO: down 29.6% S&P 500: up 9.7% | NWBO trailed the S&P 500 by 39.3 percentage points Trailed |
| Long term | ||
| 3Y | NWBO: down 79.4% S&P 500: up 68.8% −41.0% vs +19.1% a year | NWBO trailed the S&P 500 by 148.2 percentage points Trailed |
| 5Y | NWBO: down 85.5% S&P 500: up 56.9% −32.1% vs +9.4% a year | NWBO trailed the S&P 500 by 142.4 percentage points Trailed |
| 10Y | NWBO: down 63.0% S&P 500: up 252.6% −9.5% vs +13.4% a year | NWBO trailed the S&P 500 by 315.6 percentage points Trailed |
$10,000 invested in NWBO 10 years ago (Nov 4, 2016) would be worth about $3,700 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $35,257.
All-time high
$1,308.00
Closing high on . Now 100.0% below that record.
Split-adjusted daily closes since Dec 14, 2001.
Stock splits
2
Latest: 1-for-16 on . Share counts adjust after each split.
Both splits
- 1-for-16
- 1-for-15
Valuation
About Northwest Biotherapeutics Inc
Northwest Biotherapeutics is a biotechnology company focused on developing personalized immunotherapy products that are designed to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis. The Company has a broad platform technology for DCVax ® dendritic cell-based vaccines. The Company's lead program involves DCVax ® -L treatment for glioblastoma (GBM). GBM is the most aggressive and lethal form of primary brain cancer, and is an "orphan disease." The Company has completed a 331-patient Phase III trial of DCVax-L for GBM, presented the results in scientific meetings, published the results in JAMA Oncology and submitted a MAA for commercial approval in the UK. The MAA is currently undergoing review. The Company has also developed DCVax ® -Direct for inoperable solid tumor cancers. It has completed a 40-patient Phase I trial and plans to pursue Phase II trials this year. The Company previously conducted a Phase I/II trial with DCVax-L for advanced ovarian cancer together with the University of Pennsylvania.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Maryland, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- PINK
- Asset type
- Common stock
- Price history since
NWBO news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
NWBO stock FAQ
What is NWBO stock’s price today?
Northwest Biotherapeutics (NWBO) traded at $0.17 at the close on , unchanged from the previous close of $0.16. Over the past 52 weeks it has traded between $0.14 and $0.34.
If you invested $1,000 in NWBO 10 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in NWBO on would be worth about $370 at the close on , a total return of −63.0%. The same $1,000 would be worth $145 if invested five years ago, $704 if invested one year ago, and $8 if invested 20 years ago. Past performance doesn’t predict future returns.
Does NWBO pay a dividend?
Northwest Biotherapeutics hasn’t paid a dividend in the last twelve months.
What is NWBO’s 52-week high and low?
Over the past 52 weeks NWBO has traded as low as $0.14 and as high as $0.34. At $0.17 at the close on , it is 50.9% below that high and 20.6% above the low.
What is NWBO’s all-time high?
NWBO’s highest closing price was $1,308.00 on , adjusted for stock splits. At $0.17 at the close on , it is 100.0% below that record.
Has NWBO stock ever split?
Yes, twice: 1-for-15 on ; 1-for-16 on .
How has NWBO stock performed?
Including dividends and measured to the close on , NWBO has returned −27.2% so far this year and −29.6% over the past year, and −85.5% over five years (−32.1% a year). Over the same periods the S&P 500, measured by SPY, returned +8.7%, +10.9% and +67.8%. Past performance doesn’t predict future returns.
What sector and industry is Northwest Biotherapeutics in?
Northwest Biotherapeutics is in the Healthcare sector and the Biotechnology industry, and is headquartered in Maryland, USA.
What exchange does NWBO trade on?
Northwest Biotherapeutics trades on the PINK under the ticker symbol NWBO. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.